Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Total Current Assets
Avadel Pharmaceuticals PLC
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Total Current Assets
$172.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
3%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Total Current Assets
$2.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Total Current Assets
$3.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Total Current Assets
$13.7m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Total Current Assets
€202.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Total Current Assets
€2.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-11%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Total Current Assets?
Total Current Assets
172.2m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Total Current Assets amounts to 172.2m USD.
What is Avadel Pharmaceuticals PLC's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
3%
Over the last year, the Total Current Assets growth was 35%. The average annual Total Current Assets growth rates for Avadel Pharmaceuticals PLC have been 15% over the past three years , -9% over the past five years , and 3% over the past ten years .
